School of Medicine


Showing 811-820 of 847 Results

  • Helen Wilson

    Helen Wilson

    Clinical Associate Professor, Psychiatry and Behavioral Sciences

    BioDr. Wilson is a licensed clinical psychologist with expertise on the effects of trauma across the lifespan. She provides clinical services for children, adolescents, adults, and families affected by trauma and other forms of anxiety and stress. Dr. Wilson also leads an active research program focused on relationships between childhood trauma and health risk behavior in adolescence and adulthood. She is the Principal Investigator of GIRLTALK: We Talk, a longitudinal study funded by the National Institute of Child Health and Human Development (NICHD) that examines links from childhood violence exposure to dating violence and sexual risk in young women from low-income communities in Chicago. Dr. Wilson has authored or co-authored thirty journal articles and book chapters related to these topics, and she regularly presents her work at local and national conferences. She is on the editorial board of the Journal of Youth and Adolescence.

  • Jeffrey J. Wine

    Jeffrey J. Wine

    Benjamin Scott Crocker Professor of Human Biology, Emeritus

    Current Research and Scholarly InterestsThe goal is to understand how a defective ion channel leads to the human genetic disease cystic fibrosis. Studies of ion channels and ion transport involved in gland fluid transport. Methods include SSCP mutation detection and DNA sequencing, protein analysis, patch-clamp recording, ion-selective microelectrodes, electrophysiological analyses of transmembrane ion flows, isotopic metho

  • Virginia Winn

    Virginia Winn

    Associate Professor of Obstetrics and Gynecology (Reproductive and Stem Cell Biology)

    Current Research and Scholarly InterestsThe Winn Laboratory seeks to understand the unique aspects of human placental biology that contribute to pregnancy complications. Abnormalities in placental biology lead to more than 25% of pregnancy complications that impact the health of mothers and their babies. The primary focus of Dr. Winn's lab is to understand human placentation and preeclampsia pathogenesis. Both basic science and translational approaches are undertaken.

  • Terry Winograd

    Terry Winograd

    Professor of Computer Science, Emeritus

    BioProfessor Winograd's focus is on human-computer interaction design and the design of technologies for development. He directs the teaching programs and HCI research in the Stanford Human-Computer Interaction Group, which recently celebrated it's 20th anniversary. He is also a founding faculty member of the Hasso Plattner Institute of Design at Stanford (the "d.school") and on the faculty of the Center on Democracy, Development, and the Rule of Law (CDDRL)

    Winograd was a founding member and past president of Computer Professionals for Social Responsibility. He is on a number of journal editorial boards, including Human Computer Interaction, ACM Transactions on Computer Human Interaction, and Informatica. He has advised a number of companies started by his students, including Google. In 2011 he received the ACM SIGCHI Lifetime Research Award.

  • Wing Hung Wong

    Wing Hung Wong

    Stephen R. Pierce Family Goldman Sachs Professor of Science and Human Health and Professor of Biomedical Data Science

    Current Research and Scholarly InterestsCurrent interest centers on the application of statistics to biology and medicine. We are particularly interested in questions concerning gene regulation, genome interpretation and their applications to precision medicine.

  • Edward H. Wood, MD

    Edward H. Wood, MD

    Assistant Professor of Ophthalmology

    Current Research and Scholarly Interestshttp://med.stanford.edu/woodlab.html

    Edward H. Wood, MD is an assistant professor of ophthalmology practicing adult and pediatric vitreoretinal surgery at Stanford University School of Medicine. Dr. Wood engages in translational research with the goal of developing new therapies and approaches for patients without viable treatment options. He does so through leveraging the technologies of patient derived stem cells, optogenetics, and phenotypic drug screening in conjunction with active clinical research and surgical device development. Dr. Wood has filed numerous patents and founded several healthcare startups with the goal of improving patients’ quality of life. His research interests include regenerative medicine, drug discovery, and pediatric retinal disease with the ultimate goal of pursuing basic science discoveries with potential for impactful clinical translation. His research interests are significantly inspired by his patients, and he is driven towards not only delivering the highest quality of care currently available, but also in developing the future standard of care in the field of medical retina and vitreoretinal surgery.

  • Mollie Woodworth

    Mollie Woodworth

    Instructor, Ophthalmology

    Current Research and Scholarly InterestsMany types of blindness result from the neurons of the retina no longer being able to communicate with the brain due to injury or disease. In mammals, the adult retina cannot make new retinal ganglion cells (the neurons that connect the retina with the brain) to replace those that are lost. In my work, I aim to learn about normal development of retinal ganglion cells and, further, to regenerate new retinal ganglion cells if they are lost in adulthood.

  • John Fraser Wright

    John Fraser Wright

    Professor (Research) of Pediatrics (Stem Cell Transplantation)

    BioJ Fraser Wright, PhD
    Dr. Wright received his PhD in 1989 from the University of Toronto (Biochemistry) for studies
    characterizing the interaction of complement with IgM, and completed post-doctoral studies at INSERM
    / CENG Grenoble, France in molecular immunology focused on antigen processing and presentation. He
    was awarded a CRCS/ MRC Scholarship, gaining faculty appointment at the University of Toronto. In
    1996 he joined industry as a Scientist at Pasteur Sanofi, contributing there to the development of
    vaccines and cancer immunotherapies, and subsequently as Director of Development and Clinical
    Manufacturing at Avigen, a gene therapy company that pioneered AAV-based investigational gene
    therapies for hemophilia and Parkinson’s disease. In 2004 he returned to academia, establishing and
    directing the Clinical Vector Facility at the Center for Cellular and Molecular Therapeutics at Children’s
    Hospital of Philadelphia, and gaining faculty appointment at the University of Pennsylvania Perelman
    School of Medicine as professor of Pathology and Laboratory Medicine. Dr. Wright has contributed to
    several clinical development programs in gene therapy, including for Luxturna and Kymriah, the first
    gene therapies for a genetic (RPE65 deficiency) and non-genetic (CAR-T immunotherapy) disease,
    respectively, approved in the United States, and for the first gene therapy clinical trial that delivered an
    AAV-vectorized monoclonal antibody to human subjects for HIV passive immunity. He is a Co-founder of
    Spark Therapeutics, serving there and subsequently at Axovant as Chief Technology Officer. In 2019 Dr.
    Wright joined Stanford University as Professor of Pediatrics at The Center for Definitive and Curative
    Medicine (CDCM). His research program aims to address key immunological barriers to gene therapy
    through innovative approaches to viral vector design and generation, and to develop vectorized
    antibodies for serious human diseases.

  • Albert Y. Wu, MD, PhD, FACS

    Albert Y. Wu, MD, PhD, FACS

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsMy translational research focuses on using autologous stem cells to recreate a patient’s ocular tissues for potential transplantation. We are generating tissue from induced pluripotent stem cells to treat limbal stem cell deficiency in patients who are bilaterally blind. By applying my background in molecular and cellular biology, stem cell biology, oculoplastic surgery, I hope to make regenerative medicine a reality for those suffering from orbital and ocular disease.